Platelet activation in heart failure

Clinical Laboratory

Volumn 50, Issue 9-10, 2004, Pages 559-566

  Schäfer, Andreas ^a,b   Eigenthaler, Martin ^a   Bauersachs, Johann ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Anticoagulation; Endothelial function; Heart failure; Nitric oxide; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ALDOSTERONE ANTAGONIST; CLOPIDOGREL; ENDOTHELIUM DERIVED RELAXING FACTOR; EPLERENONE; LOSARTAN; NITRIC OXIDE; PADGEM PROTEIN; THROMBOXANE A2; TRANDOLAPRIL; WARFARIN; XIMELAGATRAN;

CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERCOAGULABILITY; NONHUMAN; REVIEW; RISK ASSESSMENT; SINUS RHYTHM; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOEMBOLISM; VASCULAR ENDOTHELIUM;

EID: 4744361657     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-1552.
2. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
3. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN. Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87:VI94-101.
4. Pullicino PM, Halperin JL, Thompson JLP. Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology 2000;54:288.
5. Loh E, St John Sutton M, Wun CC. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997;336:251-257.
6. Roberts WC, Siegel RJ, McManus BM. Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients. Am J Cardiol 1987;60:1340-1355.
7. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349:1019-1026.
8. Jafri SM. Hypercoagulability in heart failure. Semin Thromb Hemost 1997;23:543-545.
9. Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol 1999;33: 1424-1426.
10. Jafri SM, Ozawa T, Mammen E, Levine TB, Johnson C, Goldstein S. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J 1993;14:205-212.
11. Lip GY, Lowe GD, Metcalfe MJ, Rumley A, Dunn FG. Effects of warfarin therapy on plasma fibrinogen, von Willebrand factor, and fibrin D-dimer in left ventricular dysfunction secondary to coronary artery disease with and without aneurysms. Am J Cardiol 1995;76:453-458.
12. Sbarouni E, Bradshaw A, Andreotti F, Tuddenham E, Oakley CM, Cleland JG. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J 1994; 127:607-612.
13. O'Connor CM, Gurbel PA, Serebruany VL. Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. Am J Cardiol 1999;83:1345-1349.
14. Mehta J, Mehta P. Platelet function studies in heart disease. VI. Enhanced platelet aggregate formation activity in congestive heart failure: inhibition by sodium nitroprusside. Circulation 1979;60:497-503.
15. Heck J, Keitel D, Wüsthoff D, Gehrmann G. Frequency and pathogenesis of thrombocytopenia in cardiac failure. Dtsch Med Wochenschr 1976;101:1381-1384.
16. Ezekowitz MD, Leonard JC, Smith EO, Allen EW, Taylor FB. Identification of left ventricular thrombi in man using indium-111-labeled autologous platelets. A preliminary report. Circulation 1981;63:803-810.
17. Ezekowitz MD, Cox AC, Smith EO, Taylor FB. Failure of aspirin to prevent incorporation of Indium-111 labelled platelets into cardiac thrombi in man. Lancet 1981;318:440-443.
18. Hendra TJ, Oswald GA, Yudkin JS. Increased mean platelet volume after acute myocardial infarction relates to diabetes and to cardiac failure. Diabetes Res Clin Pract 1988;5:63-69.
19. Erne P, Wardle J, Sanders K, Lewis SM, Maseri A. Mean platelet volume and size distribution and their sensitivity to agonists in patients with coronary artery disease and congestive heart failure. Thromb Haemost 1988;59:259-263.
20. Gibbs CR, Blann AD, Watson RD, Lip GY. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: Effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation 2001;103:1746-1751.
21. Stumpf C, Lehner C, Eskafi S, Raaz D, Yilmaz A, Ropers S et al. Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur J Heart Fail 2003;5:629-637.
22. Schäfer A, Fraccarollo D, Hildemann S, Christ M, Eigenthaler M, Kobsar A et al. Inhibition of platelet activation in congestive heart failure by selective aldosterone receptor antagonism and ACE inhibition: Role of endothelial function and platelet VASP phosphorylation. Thromb Haemost 2003;89:1024-1030.
23. Teerlink JR, Loffler BM, Hess P, Maire JP, Clozel M, Clozel JP. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). Circulation 1994;90:2510-2518.
24. Fraccarollo D, Galuppo P, Hildemann S, Christ M, Ertl G, Bauersachs J. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 2003;42:1666-1673.
25. Bauersachs J, Fraccarollo D. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure. Minerva Cardioangiol 2003;51:155-164.
26. Schäfer A, Fraccarollo D, Hildemann S, Tas P, Ertl G, Bauersachs J. Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. Cardiovasc Res 2003;58:655-662.
27. Bauersachs J, Heck M, Fraccarollo D, Hildemann S, Ertl G, Wehling M et al. Addition of spironolactone to ACE inhibitor in heart failure improves endothelial vasomotor dysfunction: Role of vascular superoxide anion formation and endothelial NO synthase expression. J Am Coll Cardiol 2002;39:351-358.
28. 1 receptor antagonists and platelet activation. Nephrol Dial Transplant 2001;16 [Suppl 1]:45-49.
29. Larsson PT, Schwieler JH, Wallen NH. Platelet activation during angiotensin II infusion in healthy volunteers. Blood Coagul Fibrinolysis 2000;11:61-69.
30. Schwemmer M, Sommer O, Bassenge E. Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling. Cardiovasc Drugs Ther 2001;15:301-307.
31. Nunez A, Gomez J, Zalba LR, Mouton M, Jimenez A, Velasco S et al. Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan. J Renin Angiotensin Aldosterone Syst 2000;1:175-179.
32. Jafri SM. Hypercoagulability in heart failure. Semin Thromb Hemost 1997;23:543-545.
33. Jin J, Kunapuli S. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci U S A 1998;95:8070-8074.
34. Furchgott RF, Zawadski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-376.
35. Alheid U, Frolich JC, Forstermann U. Endothelium-derived relaxing factor from cultured human endothelial cells inhibits aggregation of human platelets. Thromb Res 1987;47:561-571.
36. Busse R, Luckhoff A, Bassenge E. Endothelium-derived relaxant factor inhibits platelet activation. Naunyn Schmiedebergs Arch Pharmacol 1987;336:566-571.
37. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-526.
38. Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A 1990;87:5193-5197.
39. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987;2:1057-1058.
40. Moro MA, Russel RJ, Cellek S, Lizasoain I, Su Y, Darley-Usmar VM et al. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci U S A 1996;93:1480-1485.
41. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 2001;88:756-762.
42. Lamontagne D, Pohl U, Busse R. Mechanical deformation of vessel wall and shear stress determine the basal release of endothelium-derived relaxing factor in the intact rabbit coronary vascular bed. Circ Res 1992;70:123-130.
43. Pohl U, Nolte C, Bunse A, Eigenthaler M, Walter U. Endothelium-dependent phosphorylation of vasodilator-stimulated protein in platelets during coronary passage. Am J Physiol 1994; 266:H606-H612.
44. Woods JD, Edwards JS, Ritter JM. Inhibition by nitro-prusside of platelet calcium mobilization: evidence for reduced sensitivity to nitric oxide in essential hypertension. J Hypertens 1993;11:1369-1373.
45. Chirkov YY, Holmes AS, Chirkova LP, Horowitz JD. Nitrate resistance in platelets from patients with stable angina pectoris. Circulation 1999;100:129-134.
46. Ellis GR, Anderson RA, Chirkov YY, Morris-Thurgood J, Jackson SK, Lewis MJ et al. Acute effects of vitamin C on platelet responsiveness to nitric oxide donors and endothelial function in patients with chronic heart failure. J Cardiovasc Pharmacol 2001;37:564-570.
47. Anderson RA, Ellis GR, Chirkov YY, Holmes AS, Payne N, Blackman DJ et al. Determinants of platelet responsiveness to nitric oxide in patients with chronic heart failure. Eur J Heart Fail 2004;6:47-54.
48. Andrews NP, Husain M, Dakak N, Quyyumi AA. Platelet inhibitory effect of nitric oxide in the human coronary circulation: impact of endothelial dysfunction. J Am Coll Cardiol 2001;37: 510-516.
49. Schäfer A, Wiesmann F, Neubauer S, Eigenthaler M, Bauersachs J, Channon KM. Rapid regulation of platelet activation in vivo by nitric oxide. Circulation 2004;109:1819-1822.
50. Corseaux D, Ollivier V, Fontaine V, Huisse MG, Philippe M, Louedec L et al. Hemostasis imbalance in experimental hypertension. Mol Med 2002;8:169-178.
51. Schäfer A, Alp NJ, Cai S, Lygate CA, Neubauer S, Eigenthaler M, et al. Reduced vascular NO bioavailability in diabetes increases platelet activation in vivo. Arterioscler Thromb Vasc Biol 2004;24:in press
52. Draijer R, Vaandrager AB, Nolte C, de Jonge HR, Walter U, van Hinsbergh V. Expression of cGMP-dependent protein kinase I and phosphorylation of its substrate, vasodilator-stimulated phosphoprotein, in human endothelial cells of different origin. Circ Res 1995;77:897-905.
53. Eigenthaler M, Nolte C, Halbruegge M, Walter U. Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their major substrates in human platelets: estimating the rate of cAMP-regulated and cGMP-regulated protein phosphorylation in intact cells. Eur J Biochem 1992;205:471-481.
54. Horstrup K, Jablonka B, Honig-Liedl P, Just M, Kochsiek K, Walter U. Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition. Eur J Biochem 1994; 225:21-27.
55. Schäfer A, Vollkommer T, Burkhardt M, Bauersachs J, Münzel T, Walter U et al. Endothelium-dependent and -independent relaxation and VASP serines 157/239 phosphorylation by cyclic nucleotide-elevating vasodilators in rat aorta. Biochem Pharmacol 2003;65:397-405.
56. Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem Pharmacol 2001;62:1153-1161.
57. Massberg S, Sausbier M, Klatt P, Bauer M, Pfeifer A, Siess W et al. Increased adhesion and aggregation of platelets lacking cyclic guanosine 3′,5′-monophosphate kinase I. J Exp Med 1999;189: 1255-1264.
58. Hauser W, Knobeloch KP, Eigenthaler M, Gambaryan S, Krenn V, Geiger J et al. Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice. Proc Natl Acad Sci U S A 1999; 96:8120-8125.
59. Oelze M, Mollnau H, Hoffmann N, Warnholtz A, Bodenschatz M, Smolenski A et al. Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction. Circ Res 2000;87:999-1005.
60. Aszódi A, Pfeifer A, Ahmad M, Glauner M, Zhou X-H, Ny L et al. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO Journal 1999;18:37-48.
61. Bearer EL, Prakash JM, Manchester RD, Allen PG. VASP protects actin filaments from gelsolin: an in vitro study with implications for platelet actin reorganizations. Cell Motil Cytoskeleton 2000;47:351-364.
62. Reinhard M, Jarchau T, Walter U. Actin-based motility: stop and go with Ena/VASP proteins. Trends Biochem Sci 2001;26: 243-249.
63. Massberg S, Grüner S, Konrad I, Garcia Arguinzonis MI, Eigenthaler M, Hemler K et al. Enhanced in vivo platelet adhesion in vasodilator-stimulated phosphoprotein (VASP)-deficient mice. Blood 2003;103:136-142.
64. Mollnau H, Wendt M, Szocs K, Lassegue B, Schulz E, Oelze M et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 2002;90:E58-E65.
65. Schulz E, Tsilimingas N, Rinze R, Reiter B, Wendt M, Oelze M et al. Functional and biochemical analysis of endothelial (dys)function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation 2002; 105:1170-1175.
66. Griffith GC, Stragnell R, Levinson DC, MOORE FJ, Ware AG. A study of the beneficial effects of anticoagulant therapy in congestive heart failure. Ann Intern Med 1952;37:867-887.
67. Khadra MD AS, Salem FACC MD, Rand PhD WM, Udelson MD FACC, Smith MD PFJ, Konstam MD FACC. Warfarin Anticoagulation and Survival: A Cohort Analysis From the Studies of Left Ventricular Dysfunction. Journal of the American College of Cardiology 1998;31:749-753.
68. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.
69. Falk RH, Pollak A, Tandon PK, Packer M. The effect of warfarin on prevalence of stroke in patients with severe heart failure. J Am Coll Cardiol 21, 218A. 1993. Abstract
70. Jones CG, Cleland JGF. Meeting report - the LIDO, HOPE, MOXCON and WASH studies. Eur J Heart Fail 1999;1:425-431.
71. De Lorenzo F, Newberry D, Scully M, Kadziola Z, Dawson G, Ranlall N et al. Low molecular weight heparin (bemiparin sodium) and the coagulation profile of patients with heart failure. Am Heart J 2002;143:689.
72. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991;84:527-539.
73. Serebruany VL, Malinin AI, Jerome SD, Lowry DR, Morgan AW, Sane DC et al. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: The Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. Am Heart J 2003;146:713-720.
74. Wolzt M, Bostrom SL, Svensson M, Wahlander K, Grind M, Sarich TC. Effects of the oral direct thrombin inhibitor ximelagatran on p-selectin expression and thrombin generation in atrial fibrillation. Pathophysiol Haemost Thromb 2003;33:68-74.
75. Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362:1691-1698.
76. Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, Nystrom P et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003;362:789-797.
77. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001;38: 2101-2113.
78. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450-1456.
79. Pitt B, Zannand F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
80. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.